“Our proprietary intranasal platform has the potential to enhance drug delivery bioavailability. We believe that intranasal delivery has the potential to improve patient outcomes by providing a ...
4 天
MyChesCo on MSNVirpax Pharmaceuticals Explores Intranasal mRNA Vaccine Delivery Using METVirpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has announced its plans to explore utilizing Molecular Envelope Technology (MET) ...
Polyrizon (PLRZ) announced that it has signed a non-binding Letter of Intent with a biotech company focused on psychedelic-derived ...
15 天
GlobalData on MSNNeOnc: bypassing the blood-brain barrier in brain cancerNeOnc claims that its novel intranasal delivery platform will be able to bypass the blood-brain barrier and better target cancer cells.
In a recent publication in Cell, researchers from the National University of Singapore and collaborators have proposed using commensal bacteria in the nasal cavity as a delivery vector for precision ...
Global Nanotechnology Drug Delivery Market is valued at USD 85.5 Billion in 2022. Global Nanotechnology Drug Delivery Market ...
Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal ...
4 天
Pharmaceutical Technology on MSNKenox and Lactiga partner on sIgA therapies for immunodeficiencyKenox and Lactiga US have announced a strategic partnership for progressing new mucosal-targeted sIgA therapies development.
Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central ...
"Our proprietary T&T platform is designed to optimize drug delivery, and we believe it holds the potential to enhance intranasal Naloxone by offering higher bioavailability for increased drug ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果